SCHEMBL10243522

SCHEMBL10243522

CCN(CCNC(=O)OC)[C@@H](C)c1ccccc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 5/20 0.45
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
HTR3A P46098 1/20 0.35
CYP3A4 P08684 2/20 0.35
PGR P06401 1/20 0.35
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
HTR2A P28223 1/20 0.35
HRH1 P35367 1/20 0.35
KCNH2 Q12809 1/20 0.35
LMNA P02545 3/20 0.34
ALDH1A1 P00352 1/20 0.34
CNR2 P34972 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243634 0.86 TSHR (0.40) MC4RPGRADRA2AADRA2BHTR2A
SCHEMBL10243117 0.86 L3MBTL1 (0.41) MEN1KMT2AALDH1A1POLB
SCHEMBL10243454 0.86 KDM4E (0.37) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL10243715 0.85 ALDH1A1 (0.43) MC4RMEN1KMT2AHTR3APGR
SCHEMBL10244008 0.85 OPRM1 (0.40) KMT2ALMNA
SCHEMBL10244104 0.84 HPGD (0.40) MC4RMEN1KMT2ALMNAALDH1A1
SCHEMBL10243705 0.84 HCRTR1 (0.43) MEN1KMT2ALMNA
SCHEMBL10243592 0.83 EPHX2 (0.43) MEN1KMT2ALMNAALDH1A1
SCHEMBL10243497 0.82 SLC22A1 (0.43) CYP3A4PGRADRA2AADRA2BHTR2A
SCHEMBL10243981 0.81 ALDH1A1 (0.48) MEN1KMT2ALMNAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MC4R 3259/4885MEN1 2456/4885KMT2A 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.